Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

This work was sponsored by Sandoz, Inc.

Declaration of financial/other relationships

AM serves on a Speakers Bureau and Steering Committee for Sandoz, Inc. He was subcontracted by Matrix45 for work on this project. KC, MB, and SB are employees of Sandoz, Inc., the study sponsor. IA and KM are employees of Matrix45, which was contracted by Sandoz, Inc. to conduct the simulations. By company policy, employees are prohibited from owning equity in client organizations (except through mutual funds or other independently administered collective investment instruments) or contracting independently with client organizations. Matrix45 provides similar services to those described in this article to other biopharmaceutical companies on a non-exclusivity basis. JME peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

None.